Mohideen Khadijah, Krithika C, Jeddy Nadeem, Shamsuddin Shaheen, Basheer Sulphi Abdul, Sainudeen Shan, Alomar Asma Ahmed, Sahly Samirah Ahmed, Mushtaq Shazia, Raj A Thirumal, Zanza Alessio, Testarelli Luca, Patil Shankargouda
Department of Oral Pathology and Microbiology, Sathyabama Dental College and Hospital, Sathyabama Institute of Science and Technology, Chennai, India.
Meenakshi Academy of Higher Education and Research, Chennai, India.
J Oral Biol Craniofac Res. 2022 May-Jun;12(3):343-351. doi: 10.1016/j.jobcr.2022.04.003. Epub 2022 Apr 14.
The systematic review is aimed to assess the antioxidant status by superoxide dismutase level in oral sub-mucous fibrosis using available literature.
A literature search was accomplished electronically in Pubmed (MeSH), Science Direct, Scopus, Web of Science core collection, Cochrane, and Cross-reference, using the keywords such as 'oral submucous fibrosis,' 'antioxidant status' and 'superoxide dismutase.'
Of the 352 articles identified, only 16 satisfied the selection criteria and were included in the systematic review. Among the selected, six studies were included for serum level analysis of superoxide dismutase. The assessment showed a significant reduction of serum superoxide dismutase in oral submucous fibrosis patients than in control (p < 0.004). The mean difference in serum superoxide dismutase concentration between oral submucous fibrosis and healthy subjects was -86.23 U/ml (95% CI -145.30, -27.17). The serum SOD level was significantly reduced as the disease progressed to stage I or stage II (p < 0.001) compared to the control group.
The studies showed significantly lower levels of superoxide dismutase in various human samples of patients with OSMF. Therefore, further studies are required to estimate antioxidant status using different biomarkers of oral submucous fibrosis concerning different stages of the disease in order to augment future therapy.
Assessment of antioxidant activity helps to identify the patients at risk of malignant transformation. It serves as a reliable guide to validate therapy. It serves as a marker of prognosis in patients suffering from oral submucous fibrosis.
本系统评价旨在利用现有文献,通过超氧化物歧化酶水平评估口腔黏膜下纤维化的抗氧化状态。
通过电子方式在PubMed(医学主题词)、Science Direct、Scopus、科学引文索引核心合集、Cochrane和CrossRef中进行文献检索,使用“口腔黏膜下纤维化”、“抗氧化状态”和“超氧化物歧化酶”等关键词。
在检索到的352篇文章中,只有16篇符合纳入标准并被纳入本系统评价。在所选文章中,有6项研究纳入了超氧化物歧化酶血清水平分析。评估显示,口腔黏膜下纤维化患者的血清超氧化物歧化酶水平显著低于对照组(p < 0.004)。口腔黏膜下纤维化患者与健康受试者血清超氧化物歧化酶浓度的平均差异为-86.23 U/ml(95%可信区间-145.30,-27.17)。与对照组相比,随着疾病进展到I期或II期,血清超氧化物歧化酶水平显著降低(p < 0.001)。
研究表明,口腔黏膜下纤维化患者的各种人体样本中超氧化物歧化酶水平显著降低。因此,需要进一步研究,利用与口腔黏膜下纤维化不同阶段相关的不同生物标志物来评估抗氧化状态,以加强未来的治疗。
评估抗氧化活性有助于识别有恶变风险的患者。它是验证治疗的可靠指南。它是口腔黏膜下纤维化患者预后的标志物。